|
|
|
|
|
by skissane
794 days ago
|
|
That may be a factor, but it is likely more complex than just that. SSRIs can cause some individuals to become disinhibited, impulsive. It is a particularly common symptom in children and adolescents (which is why many paediatricians and child psychiatrists hesitate to prescribe them), but more rarely can happen in adults too. Probably some people have a genetic susceptibility to it. It isn’t purely about ameliorating depression, since the same side effect has been observed in non-depressed children administered SSRIs (which aren’t solely used to treat depression, sometimes they are used to treat anxiety too, plus some children can end up being prescribed them when they have neither, due to misprescribing or off-label use.) Disinhibition and increased impulsivity can increase the risks of suicidality/homicidality/etc |
|
Anecdotal, but I've never once met a doctor who adequately described the risks of an SSRI to me as a patient, and even some who have pushed back when I've told them of my own dangerous reactions and other risk factors the drugs have. They really should, as should the risks of new psychedelic based drugs hitting the market. I don't have a problem with the study that's posted. What I do have a problem with is that I feel as if this information is going to be disproportionately used to deny access to RX psychedelics, when existing RXs with similar or worse risk factors aren't discussed in this manner at all.